Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

The Company Behind Tylenol Tries to Navigate Its Latest Crisis

Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Drugs (Pharmaceuticals), Intellectual Disabilities, Johnson & Johnson, Kennedy, Robert F Jr, Mergers, Acquisitions and Divestitures, Pain-Relieving Drugs, Recalls and Bans of Products, Trump, Donald J, Tylenol (Drug)
←Jimmy Kimmel’s Show to Return to ABC on Tuesday Night
Make T Something | Nonamey→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube